From: Development and validation of prognostic markers in sarcomas base on a multi-omics analysis
Clinical features | Total | iC2 | iC1/iC3/iC4 | P value |
---|---|---|---|---|
Event | Â | Â | Â | 0.27 |
 Alive | 155 | 23 | 132 |  |
 Dead | 94 | 23 | 71 |  |
Age | Â | Â | Â | 0.0134 |
 0–50 | 51 | 8 | 43 |  |
 50–60 | 65 | 9 | 56 |  |
 60–70 | 67 | 10 | 57 |  |
 70–80 | 44 | 11 | 33 |  |
 80–100 | 22 | 8 | 14 |  |
Gender | Â | Â | Â | 0.33 |
 Female | 135 | 26 | 109 |  |
 Male | 114 | 20 | 94 |  |
HistologicalType | Â | Â | Â | 0.203 |
 DL | 57 | 2 | 55 |  |
 DT | 2 |  | 2 |  |
 LMS | 100 | 14 | 86 |  |
 MFS | 23 | 6 | 17 |  |
 MPNST | 8 | 1 | 7 |  |
 SS | 10 |  | 10 |  |
 UPS | 49 | 23 | 26 |  |
NewEventType | Â | Â | Â | 0.357 |
 DistantMetastasis | 67 | 19 | 48 |  |
 LocoregionalDisease | 1 |  | 36 |  |
 LocoregionalRecurrence | 48 | 4 | 14 |  |
 NewPrimaryTumor | 8 | 2 | 1 |  |
 Primary | 125 | 21 | 104 |  |